Drug Profile

E 21R

Alternative Names: E21R

Latest Information Update: 19 Mar 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hanson Centre for Cancer Research
Class Antineoplastics
Mechanism of Action Apoptosis stimulants; Granulocyte macrophage colony stimulating factor antagonists; Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Rheumatoid arthritis

Most Recent Events

01 Sep 2003 E 21R is available for licensing (http://www.bresagen.com.au)
11 Apr 2003 BresaGen has begun discussions with a major pharmaceutical company for collaborative development of E 21R
11 Apr 2003 Discontinued - Phase-II for Chronic myelomonocytic leukaemia in Australia (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com